Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 19, 2005

Primary Completion Date

April 5, 2010

Study Completion Date

May 17, 2013

Conditions
Lymphoma
Interventions
DRUG

lenalidomide

10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.

Trial Locations (3)

94305-5824

Stanford Cancer Center, Stanford

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00466921 - Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome | Biotech Hunter | Biotech Hunter